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論 文 内 容 要 旨
IL-37 is a newly defined member of the IL-1 cytokine family. IL-37 expressed only in certain 
types of human organs and cells such as; testis, thymus, uterus, kidney, heart, peripheral blood 
mononuclear cells (PBMCs) and dendritic cells. It has been reported that IL-37 inhibited innate 
immunity and inflammatory respons es in autoimmune diseases and tumors. Osteoclast recruitment 
might be central to diseases involving bone erosion, such as rheumatoid arthritis. Osteoclasts derived 
from bone marrow cells regulate bone resorption and remodeling. Two factors are required for 
osteoclasts formation and activation: receptor activator of NF-kB ligand (RANKL) and macrophage 
colony stimulating factor (M-CSF). It has also been reported that tumor necrosis factor (TNF)- α 
induced osteoclast formation in vitro and in vivo . Lipopolysaccharide (LPS), which is a bacterial 
cell wall component, is known as a potent inducer of inflammation. LPS is able to induce osteoclast 
formation and pathological bone resorption. LPS is also recognized to induce the production of 
many local factors, including proinflammatory cytokine such as TNF-α and IL-1, from macrophages 
or other cells in inflammatory site. These cytokines have been reported to associate with LPS-
induced osteoclast formation and bone destruction in vivo and in vitro studies. Moreover, it has 
been reported that LPS stimulates osteoblasts to produce or secrete RANKL. IL-37 also inhibited 
Lipopolysaccharide (LPS)-induced immunological reaction. However, there is no study to investigate 
the effect of IL-37 on LPS-induced osteoclast formation and bone resorption. The purpose of this 
study is to investigate the effect of IL-37 in LPS-induced osteoclast formation and bone resorption.
  LPS was administrated with or without IL-37 by subcutaneous injection on supracalvariae of 
mice. The number of osteoclasts, the level of mRNA for cathepsin K and tartrate-resistant acid 
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phosphatase (TRAP), and the level of C-Terminal Telopeptide Fragments of Type I Collagen Cross-
Links as a marker of bone resorption in mice administrated both LPS and IL-37 were lower than 
that in mice administrated LPS alone. Mice calvariae were observed using microfocal computed 
tomography images, many bone destruction spots were seen in the group administered LPS. The 
ratio of the bone destruction area in the LPS administered group was significantly higher than 
that in the PBS group and IL-37 alone administrated group. In addition, in the LPS and IL-37 
administered groups, bone destruction was lower than that in the LPS alone administered group.
Real-time RT-PCR was performed to analyze osteoclast related cytokines RANKL, TNF-α and IL-1β 
mRNA levels in vivo. RANKL, TNF-α and IL-1β mRNA was increased in the LPS administrated mice 
as compared with PBS administrated groups. On the other hand, RANKL, TNF-α and IL-1β mRNA 
was inhibited in the IL-37 and LPS administrated mice as compared with LPS alone administrated group. 
In vitro analysis, there was no effect of IL-37 in RANKL-induced osteoclast formation, TNF-α -induced 
osteoclast formation and cell viability from bone marrow macrophages as osteoclast precursor and LPS-
induced RANKL expression from stromal cells. 
These results indicated that IL-37 inhibited LPS-induced osteoclast formation and bone resorption 
via inhibition of LPS-induced osteoclast related cytokines, but might not directly inhibit osteoclast 
formation on osteoclast precursor and RANKL expression on stromal cells.
審 査 結 果 要 旨
Osteoclast recruitment plays an important role in bone diseases such as rheumatoid arthritis. 
Osteoclast formation in bone disease is regulated by inflammatory response including bacterial 
infection and cytokines such as TNF- α , receptor activator of NF- κ B ligands (RANKL) and 
macropharge colony stimulating factor (M-CSF). Lipopolysaccharide (LPS) is a potent inducer of 
inflammation and pathogen of inflammatory bone loss through the production of inflammatory 
cytokines including TNF- α , IL-1 and RANKL. Thus inhibition of inflammatory response that 
involved in osteoclast formation is critical in suppressing bone destruction of rheumatoid arthritis. 
IL-37 is a new member of the IL-1 cytokine family that expressed certain type of the human organs 
such as testis, thymus, uterus, kidney, heart, peripheral blood mononuclear cells and dendritic 
cells. It has been reported that IL-37 inhibited innate immunity and inflammatory responses in 
autoimmune diseases and tumors. However, no study examined the effect of IL-37 on osteoclast 
formation induced by inflammatory response.
This study is attempted to investigate effect of IL-37 on LPS-induced osteoclast formation and 
bone resorption. LPS was administrated with or without IL-37 to supracalvariae of mice. Results 
indicated that expressions of mRNA for cathepsin K and tartrate-resistant acid phosphatase (TRAP) 
as markers for osteoclast formation were decreased in LPS and IL-37 administration group compared 
with LPS alone administration group. Amount of C-terminal telopeptide fragment of type I collagen, 
a maker of bone destruction was also decreased by administration of IL-37. Microfocal computed 
tomography analysis demonstrated that spots of bone destruction were signiﬁcantly decreased in 
the LPS and IL-37 administration group. The mRNA expressions of osteoclast related cytokines such 
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as RANKL, IL-1 β and TNF- α were also decreased in the LPS and IL-37 administration group 
compared with LPS alone administration group. However RANKL induced-osteoclast formation 
using bone marrow derived cells as osteoclast precursors were not inhibited by the treatment with 
IL-37.
From these findings, the author concluded that IL-37 inhibited LPS-induced bone resorption 
through the inhibition of production of osteoclast related mediators such as RANKL, TNF- α and 
IL-1 β in mice model. However, IL-37 did not inhibit the osteoclastgenesis induced by RANKL or 
TNF- α in murine bone marrow cells culture. These data indicated that IL-37 inhibited LPS induced 
bone resorption by inhibiting expression of LPS-induced osteoclast related genes, but it did not 
directly affect function of osteoclasts.
As the manuscript presented is a very well thought out and very well written, it is suitable to 
Ph.D thesis.
